carbamates has been researched along with Parkinson Disease in 22 studies
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function." | 9.10 | Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003) |
| "The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition." | 5.31 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002) |
| " We studied the effects of rivastigmine on the qEEG in Parkinson's disease (PD) patients with dementia." | 5.10 | Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients. ( Fogelson, N; Giladi, N; Kogan, E; Korczyn, AD; Neufeld, MY; Shabtai, H, 2003) |
| "Rivastigmine may improve the cognitive functions in PD patients with dementia with no worsening of motor function." | 5.10 | Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. ( Anca, M; Benbunan, B; Giladi, N; Gurevich, T; Korczyn, AD; Shabtai, H, 2003) |
| "Pain is a prevalent PD's non-motor symptom with a higher prevalence of analgesic drugs prescription for patients." | 1.56 | Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease. ( Bortolanza, M; Crivelaro do Nascimento, G; Del Bel, EA; Ferrari, DP; Ferreira-Junior, NC; Guimaraes, FS, 2020) |
| "Parkinson's disease is a major age-related neurodegenerative disorder." | 1.38 | Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase. ( Greig, NH; Kamal, MA; Nawaz, MS; Parveen, Z; Shakil, S, 2012) |
| "In models of Parkinson's disease, indirect-pathway eCB-LTD is absent but is rescued by a D2 receptor agonist or inhibitors of endocannabinoid degradation." | 1.34 | Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models. ( Kreitzer, AC; Malenka, RC, 2007) |
| "The observation that patients with Parkinson's disease dementia have extensive cholinergic deficits led to the hypothesis that cholinesterase inhibitors may provide benefits for patients with this condition." | 1.31 | Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. ( Bullock, R; Cameron, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.55) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (40.91) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 5 (22.73) | 2.80 |
| Authors | Studies |
|---|---|
| Ebrahimi-Ghiri, M | 1 |
| Shahini, F | 1 |
| Zarrindast, MR | 1 |
| Viel, C | 2 |
| Clarke, J | 2 |
| Kayatekin, C | 1 |
| Richards, AM | 2 |
| Chiang, MSR | 1 |
| Park, H | 2 |
| Wang, B | 2 |
| Shihabuddin, LS | 2 |
| Sardi, SP | 2 |
| Crivelaro do Nascimento, G | 1 |
| Ferrari, DP | 1 |
| Guimaraes, FS | 1 |
| Del Bel, EA | 1 |
| Bortolanza, M | 1 |
| Ferreira-Junior, NC | 1 |
| Zhao, L | 1 |
| Bai, F | 1 |
| Chen, F | 1 |
| Guo, M | 1 |
| Gan, L | 1 |
| Zhang, H | 1 |
| Fang, J | 1 |
| Videnovic, A | 1 |
| Amara, AW | 1 |
| Comella, C | 1 |
| Schweitzer, PK | 1 |
| Emsellem, H | 1 |
| Liu, K | 1 |
| Sterkel, AL | 1 |
| Gottwald, MD | 1 |
| Steinerman, JR | 1 |
| Jochelson, P | 1 |
| Zomorodi, K | 1 |
| Hauser, RA | 1 |
| Narayan, S | 1 |
| Liew, Z | 1 |
| Bronstein, JM | 1 |
| Ritz, B | 1 |
| Nury, C | 1 |
| Redeker, V | 1 |
| Dautrey, S | 1 |
| Romieu, A | 1 |
| van der Rest, G | 1 |
| Renard, PY | 1 |
| Melki, R | 1 |
| Chamot-Rooke, J | 1 |
| Chuang, CS | 1 |
| Su, HL | 1 |
| Lin, CL | 1 |
| Kao, CH | 1 |
| Viveros-Paredes, JM | 1 |
| Gonzalez-Castañeda, RE | 1 |
| Escalante-Castañeda, A | 1 |
| Tejeda-Martínez, AR | 1 |
| Castañeda-Achutiguí, F | 1 |
| Flores-Soto, ME | 1 |
| Treleaven, CM | 1 |
| Olszewski, MA | 1 |
| Dodge, JC | 1 |
| Marshall, J | 1 |
| Makino, E | 1 |
| Sidman, RL | 1 |
| Cheng, SH | 1 |
| Chabwine, JN | 1 |
| Rossetti, AR | 1 |
| Hirt, L | 1 |
| Kuntzer, T | 1 |
| Schluep, M | 1 |
| Michel, P | 1 |
| Démonet, JF | 1 |
| du Pasquier, RA | 1 |
| Vingerhoets, FG | 1 |
| Parveen, Z | 1 |
| Nawaz, MS | 1 |
| Shakil, S | 1 |
| Greig, NH | 1 |
| Kamal, MA | 1 |
| Bullock, R | 1 |
| Cameron, A | 1 |
| Fogelson, N | 1 |
| Kogan, E | 1 |
| Korczyn, AD | 2 |
| Giladi, N | 2 |
| Shabtai, H | 2 |
| Neufeld, MY | 1 |
| Dautzenberg, PL | 1 |
| Wouters, CJ | 1 |
| Oudejans, I | 1 |
| Samson, MM | 1 |
| Youdim, MB | 1 |
| Amit, T | 1 |
| Bar-Am, O | 1 |
| Weinstock, M | 1 |
| Yogev-Falach, M | 1 |
| GILLHESPY, RO | 1 |
| Gurevich, T | 1 |
| Benbunan, B | 1 |
| Anca, M | 1 |
| Kreitzer, AC | 1 |
| Malenka, RC | 1 |
| Lawson, K | 1 |
| Reading, PJ | 1 |
| Luce, AK | 1 |
| McKeith, IG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness[NCT03037203] | Phase 2 | 66 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change from Baseline ESS defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4).~The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions, asking subjects how likely they would be to doze off or fall asleep in different situations. Responses range from 0 = would never doze to 3 = high chance of dozing. Higher scores represent greater severity of excessive sleepiness. The total score ranges from 0 - 24, with higher scores representing greater severity of excessive sleepiness." (NCT03037203)
Timeframe: Baseline to Weeks 1, 2, 3, and 4
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| JZP-110 75mg | -4.82 |
| JZP-110 150mg | -5.04 |
| JZP-110 300mg | -5.72 |
| Placebo | -4.78 |
"Change from Baseline mean sleep latency (in minutes) on the MWT defined in terms of change from study baseline (prior to first dose in Period 1) to the end of each Treatment Period (Weeks 1, 2, 3, and 4).~The MWT is the standard objective measure of an individual's ability to remain awake during the daytime in a darkened, quiet environment. MWT sleep latency ranges from 0 to 40 minutes, with higher scores indicated greater ability to stay awake." (NCT03037203)
Timeframe: Baseline to Weeks 1, 2, 3, and 4
| Intervention | minutes (Least Squares Mean) |
|---|---|
| JZP-110 75mg | 0.4289 |
| JZP-110 150mg | 2.6721 |
| JZP-110 300mg | 6.8133 |
| Placebo | 1.7670 |
(NCT03037203)
Timeframe: Up to Day 35
| Intervention | Participants (Count of Participants) |
|---|---|
| JZP-110 75mg | 1 |
| JZP-110 150mg | 2 |
| JZP-110 300mg | 0 |
| Placebo | 0 |
2 reviews available for carbamates and Parkinson Disease
| Article | Year |
|---|---|
Is there a role for potassium channel openers in neuronal ion channel disorders?
Topics: Aminopyridines; Animals; Anticonvulsants; Antihypertensive Agents; Ataxia; Carbamates; Diazoxide; Ep | 2000 |
Understanding changes in cholinergic function: implications for treating dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibi | 2002 |
4 trials available for carbamates and Parkinson Disease
| Article | Year |
|---|---|
Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
Topics: Adult; Carbamates; Disorders of Excessive Somnolence; Double-Blind Method; Humans; Parkinson Disease | 2021 |
Effects of rivastigmine on the quantitative EEG in demented Parkinsonian patients.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Dementia; Elec | 2003 |
Rivastigmine (Exelon) for dementia in patients with Parkinson's disease.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Cognition; Dementia; Humans; Male; Parkinson Disease; P | 2003 |
Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
Topics: Aged; Carbamates; Caregivers; Cognition Disorders; Female; Follow-Up Studies; Hallucinations; Humans | 2001 |
16 other studies available for carbamates and Parkinson Disease
| Article | Year |
|---|---|
The effect of URB597, exercise or their combination on the performance of 6-OHDA mouse model of Parkinson disease in the elevated plus maze, tail suspension test and step-down task.
Topics: Animals; Behavior, Animal; Benzamides; Carbamates; Disease Models, Animal; Elevated Plus Maze Test; | 2021 |
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model.
Topics: Animals; Carbamates; Disease Models, Animal; Glucosylceramidase; Glucosylceramides; Glucosyltransfer | 2021 |
Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Topics: Amidohydrolases; Analgesics; Animals; Benzamides; Brain; Cannabidiol; Capsaicin; Carbamates; Celecox | 2020 |
A β-allyl carbamate fluorescent probe for vicinal dithiol proteins.
Topics: Carbamates; Fluorescent Dyes; Humans; Parkinson Disease; Proteins; Sulfhydryl Compounds | 2020 |
Occupational pesticide use and Parkinson's disease in the Parkinson Environment Gene (PEG) study.
Topics: Adult; California; Carbamates; Case-Control Studies; Fungicides, Industrial; Herbicides; Humans; Hyd | 2017 |
A novel bio-orthogonal cross-linker for improved protein/protein interaction analysis.
Topics: alpha-Synuclein; Amino Acid Sequence; Azides; Carbamates; Chromatography, Liquid; Cross-Linking Reag | 2015 |
Risk of Parkinson disease after organophosphate or carbamate poisoning.
Topics: Adult; Aged; Carbamates; Cohort Studies; Databases, Factual; Female; Humans; Male; Middle Aged; Orga | 2017 |
Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amidohydrolases; Animals; Benzamides; Carbamates; Dise | 2019 |
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models.
Topics: alpha-Synuclein; Animals; Carbamates; Disease Models, Animal; Enzyme Inhibitors; Gene Expression Reg | 2017 |
[Neurology].
Topics: Antibodies, Monoclonal; Anticonvulsants; Atrial Fibrillation; Carbamates; Chronic Disease; Deep Brai | 2012 |
Molecular docking study of catecholamines and [4-(propan-2-yl) phenyl]carbamic acid with tyrosine hydroxylase.
Topics: Amino Acid Sequence; Animals; Carbamates; Catecholamines; Dopamine; Humans; Ligands; Models, Molecul | 2012 |
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
Topics: Aged; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Hallucinations; Humans; Male; Parkins | 2002 |
Rivastigmine in prevention of delirium in a 65 years old man with Parkinson's disease.
Topics: Aged; Aortic Valve Insufficiency; Carbamates; Cholinesterase Inhibitors; Colitis, Ulcerative; Deliri | 2003 |
Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Carbamates; Cell Line; Enzyme Activation | 2003 |
Methylpentynol carbamate in the management of insomnia and parkinsonism.
Topics: Anxiety; Carbamates; Humans; Parkinson Disease; Parkinsonian Disorders; Sleep Initiation and Mainten | 1958 |
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models.
Topics: Animals; Benzamides; Benzoxazines; Cannabinoid Receptor Modulators; Carbamates; Disease Models, Anim | 2007 |